<DOC>
	<DOCNO>NCT00242268</DOCNO>
	<brief_summary>The purpose study determine use Avonex combination Zocor safe effective therapy subject relapse remit multiple sclerosis .</brief_summary>
	<brief_title>A Safety Study Combination Treatment With Avonex Zocor Relapsing Remitting Multiple Sclerosis</brief_title>
	<detailed_description>Multiple Sclerosis ( MS ) inflammatory demyelinate disease Central Nervous System ( CNS ) . There many form MS ; althoughthe majority Relapsing Remitting ( RRMS ) represent approximately 80 % case . The disease appear inflammatory RRMS manisfested increase inGadolinium enhancement MRI increase inflammatory bioassay marker . Zocor class drug ( statin ) use low cholesterol . Statins also anti-inflammatory effect CNS . Zocor show small clinical trial reduce number new MRI-detected brain lesion six month treatment period patient RRMS . This study evaluate safety combine Avonex Zocor period fourteen month patient RRMS evaluate effect treatment new enlarge lesion measure MRI .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>1 . Male nonpregnant female age 1855 clinically laboratory definite relapsingremitting MS use MacDonald criterion . 2 . Subjects must take form interferon therapy ( Rebif , Avonex Betaseron ) duration 12 month document breakthrough disease define : = 1 document clinical relapse past 12 month interferon therapy . For eligibility , prestudy relapse define neurologic symptom sign document review history subject medical record , sufficient severity duration determine investigator consistent acute MS relapse . The relapse need treat qualify . time relapse define base onset symptom . OR &gt; = 1 document Gdenhancing lesion cranial spinal MRI . The presence Gdenhancing lesion must document either report medical record review film investigator . 3 . The Kurtzke EDSS score must 0 5.0 . 4 . All subject must give write consent prior evaluation test . 1 . Subjects primary secondary progressive MS. 2 . Female patient may pregnant , attempt pregnancy breastfeeding . 3 . Female subject must use acceptable form contraception study define investigator . The rhythm method use sole method contraception . 4 . Subjects unwilling unable give inform consent . 5 . Subjects NAB+ ( titer &gt; = 20 ) . 6 . Abnormal baseline blood test exceed limit define : 1 . ALT AST &gt; 2x upper limit normal ( ULN ) 2 . CPK &gt; 2x upper limit normal ( ULN ) 3 . Total WBC &lt; 3,000/mm3 7 . No chronic infection ( include HIV Hepatitis B/C ) may present .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2005</verification_date>
</DOC>